Biotech releases results from exploratory phase II trialEdmonton-based BioMS Medical Corp. (TSX: T.MS, Stock Forum) announced results Friday from MINDSET-01, an exploratory phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II evaluating dirucotide in patients with relapsing-remitting MS. According to the company, “the results of the MINDSET-01 study showed that dirucotide did not meet its primary endpoint, annualized annualized Of or relating to a variable that has been mathematically converted to a yearly rate. Inflation and interest rates are generally annualized since it is on this basis that these two variables are ordinarily stated and compared. relapse rate or associated secondary MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. endpoints. Dirucotide did meet certain secondary endpoints related to the progression of the disease, including mean change from baseline in the Expanded Disability Status Scale The Kurtzke Expanded Disability Status Scale (EDSS) is a method of quantifying disability in multiple sclerosis.[1] The EDSS quantifies disability in eight Functional Systems (FS) and allows neurologists to assign a Functional System Score (FSS) in each of these. (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) score.” The data also showed that dirucotide was generally well tolerated. BioMS says it and its partner Eli Lilly & Company (NYSE NYSE See: New York Stock Exchange : LLY, Stock Forum) will continue to analyze the results of the exploratory phase II trial. "We are encouraged that dirucotide has demonstrated an effect on certain clinical measures of disease progression, this time in the earlier form of the disease," said Kevin Giese, president and CEO of BioMS Medical. "Dirucotide was developed as a potential treatment for patients with progressive MS and we believe that these results are consistent with the nature of the therapy, and what is understood about dirucotide's method of action." 
|
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion